TMO Stock Forecast & Price Target

Thermo Fisher Scientific is supported by a resilient, diversified portfolio that is showing clearer demand acceleration, with 3Q organic revenue growth of about 6% and adjusted EPS of $6.68 on $12.14 billion of revenue, while operating margin expanded 120 bps to 24.5%. Strength was broad enough to validate the constructive outlook, led by Lab Products and Biopharma Services at roughly 10% organic growth and Analytical Instruments at about 6%, while pharma/biotech demand improved and China accelerated to low-double-digit growth. Management also raised FY26 revenue guidance to $47.7–48.2 billion and EPS to $25.13–$25.43, alongside expected 80 bps EBIT margin expansion and $7.0–$7.5 billion of free cash flow, reinforcing confidence in continued growth and execution.

Thermo Fisher Scientific is viewed negatively because its growth trajectory appears well below its historical standard, with company guidance of roughly 3% to 4% organic sales growth in 2026 versus a long-term target of 7%, suggesting the market may not reward the business with a premium multiple. The outlook is further pressured by the risk that end-market normalization in scientific lab supply takes longer than expected, or never fully arrives, after years of false starts, while its ability to repeat the value-creating M&A strategy that once supported shareholder returns has become more limited as attractive targets have become scarcer. In addition, AI-related concerns could weigh on about 20% of sales from clinical research and roughly 40% from scientific research supply, as automation and a shift from wet lab to dry lab work may erode demand.